Tuberculosis screening in an aged care residential facility in a low-incidence setting

Nompilo Moyo, James McCracken Trauer, Peter Trevan, Ann-Marie Baker, Joseph Musemburi, Kerry McGrath, Aine Nolan, Eaomn McIntyre, Jane Hulls, Justin T Denholm

Research output: Contribution to journalArticleResearchpeer-review


Tuberculosis (TB) remains a disease of high morbidity in Australia, with implications for both public health and the individual. Cost analyses is relevant for programmatic evaluation of TB. There is minimal published TB cost data in the Australian setting. Patients with drug sensitive active pulmonary TB (DS-PTB) and latent TB (LTBI) were enrolled in a single tertiary referral centre to evaluate healthcare provider costs. The median cost of treating drug susceptible pulmonary TB in this case series was 11,538 AUD. Approximately 50% of total costs is derived from inpatient hospitalisation bed days. In comparison, the average cost of managing latent TB was 582 AUD per completed course. We find the median provider cost of our DS-PTB treatment group comparable to costs from other regions globally with similar economic profiles. A program designed to detect and treat LTBI to prevent subsequent disease may be cost effective in appropriately selected patients and warrants further study.

Original languageEnglish
Pages (from-to)E209-E211
Number of pages3
JournalCommunicable Diseases Intelligence Quarterly Report
Issue number3
Publication statusPublished - 1 Sep 2017

Cite this